Zevra Therapeutics at Canaccord Genuity: growth plan widens

On Tuesday, 11 August 2026, Zevra Therapeutics (ZVRA) shared a more extensive growth strategy for its rare-disease portfolio during Canaccord Genuity's 46th Annual Growth Conference. The company focused on MIPLYFFA for Niemann-Pick disease type C (NPC), which has shown encouraging U.S. uptake and a larger-than-expected adult patient base.

While acknowledging regulatory challenges in Europe and the need to advance celiprolol for vascular Ehlers-Danlos syndrome, Zevra emphasized MIPLYFFA as its primary commercial focus. The drug, approved in the U.S. for NPC, has recorded 184 cumulative prescription enrollment forms, representing 184 distinct patients. Investor interest has been positive, with shares up approximately 35% over the last six months and 28% year-to-date, resulting in a market capitalization of around $676 million.

CEO Neil McFarlane noted that the company is encountering more newly diagnosed patients than anticipated, which has expanded the perceived market. Management highlighted that adults account for about half of NPC enrollments, a shift from the historical view of NPC as a childhood disease. Zevra cited expanded access data, including a four-year follow-up, that reinforce the presence of a significant adult cohort.

The company's pricing for MIPLYFFA has remained close to its original guidance, with adjustments only by a few hundred dollars. Zevra is employing various strategies to increase awareness and patient diagnosis, including physician education, patient group outreach, genetic testing support, and publications. The company is also learning from the more mature NPC market in Europe, which has approximately 1,100 prevalent patients, to guide the U.S. market growth.

Zevra submitted a re-examination request to the European Medicines Agency for MIPLYFFA following a negative opinion. Management remains confident in the growing evidence package, which now supports the same direction. Additionally, Zevra discussed celiprolol, its Phase III program for vascular Ehlers-Danlos syndrome, which is crucial due to the lack of approved therapies for VEDS in the U.S. The company sees potential in new entrants in the NPC field, such as IntraBio's AQNEURSA and pipeline programs from Berin and Rafael/Cyclo, which may raise disease awareness and increase testing, ultimately expanding the market.

Zevra's strong balance sheet, with $260 million in cash and equivalents, no debt, a current ratio of 5.17, and a gross profit margin of roughly 95%, positions it well to continue investing in its growth initiatives. Zevra's priorities include U.S. MIPLYFFA growth, geographic expansion, and celiprolol development. Management stressed that the $85,000 monthly WAC for MIPLYFFA should remain steady unless there is a significant shift in the adult-to-pediatric mix.

Analysts on Wall Street generally view ZVRA positively, with price targets ranging from $20 to $35 per share. Investors can find a more detailed analysis in ZVRA's Pro Research Report, which provides clear and actionable intelligence on the company's financial data.